Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27659428)

Published in Sci Rep on September 23, 2016

Authors

Hongmei Wang1,2,3, Xusheng Zhang2,3, Xiufen Zheng2,3, Zhu Lan3, Jun Shi1, Jifu Jiang3, Terry Zwiep2,3, Qing Li1,2, Douglas Quan2,3, Zhu-Xu Zhang1,2,3, Weiping Min1,2,3

Author Affiliations

1: Institute of Immunotherapy and Medical College of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.
2: Department of Surgery, Pathology, and Oncology, University of Western Ontario, London, Canada.
3: Multi-Organ Transplant Program, London Health Sciences Centre, London, Canada.

Articles cited by this

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73

T cell exhaustion. Nat Immunol (2011) 11.08

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol (2003) 5.07

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79

Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72

Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66

Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity (2010) 4.06

Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05

Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity (2008) 3.48

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18

Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08

Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26

RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev (2003) 2.19

Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood (2003) 2.12

Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med (2005) 2.10

Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol (2007) 2.08

Regulatory immune cells in transplantation. Nat Rev Immunol (2012) 1.82

Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol (2013) 1.70

De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol (2008) 1.52

PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol (2007) 1.51

Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol (2003) 1.41

TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene (2008) 1.41

Role of the PD-1 pathway in the immune response. Am J Transplant (2012) 1.35

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol (2013) 1.33

Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology (2008) 1.33

Tolerogenic dendritic cells and their role in transplantation. Semin Immunol (2011) 1.26

Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol (2008) 1.21

Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes (2013) 1.17

Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf (2012) 1.17

Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol (2008) 1.14

Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J Clin Invest (2014) 1.13

Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice. Transplantation (2009) 1.12

Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets (2008) 1.11

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol (2013) 1.10

Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol (2007) 1.10

Retracted Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nat Immunol (2013) 1.09

Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) (2014) 1.07

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clin Cancer Res (2015) 1.05

Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation (2006) 0.98

Regulatory T cell induction, migration, and function in transplantation. J Immunol (2012) 0.96

Costimulation blockade: current perspectives and implications for therapy. Transplantation (2013) 0.95

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol (2015) 0.95

The role of coinhibitory signaling pathways in transplantation and tolerance. Front Immunol (2012) 0.95

Regulatory T cells and Toll-like receptors: what is the missing link? Int Immunopharmacol (2009) 0.94

Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther (2014) 0.93

Induction of alloimmune tolerance in heart transplantation through gene silencing of TLR adaptors. Am J Transplant (2012) 0.89

Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood (2013) 0.89

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife (2016) 0.89

Immune responses of macrophages and dendritic cells regulated by mTOR signalling. Biochem Soc Trans (2013) 0.85

T cell exhaustion and Interleukin 2 downregulation. Cytokine (2014) 0.85

The role of positive costimulatory molecules in transplantation and tolerance. Curr Opin Organ Transplant (2008) 0.85

Immunosuppressive drugs after solid organ transplantation. Neth J Med (2013) 0.84

Immunotherapies: the blockade of inhibitory signals. Int J Biol Sci (2012) 0.82

The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses. Nutrients (2013) 0.82

mTOR signaling, Tregs and immune modulation. Immunotherapy (2014) 0.82

T-cell exhaustion in allograft rejection and tolerance. Curr Opin Organ Transplant (2015) 0.82

Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant (2014) 0.81

Roles of Toll-like receptors in transplantation. Curr Opin Organ Transplant (2014) 0.81

Abrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways. Transplantation (2013) 0.80

Immune Exhaustion and Transplantation. Am J Transplant (2016) 0.76